Key Highlights

● A 1-for-25 reverse split took effect before the open on October 5.

● Second-quarter Revenue was $343,639, up from $56,325 in the first quarter.

● Cash, equivalents and restricted cash were about $11.2 million at June 30.

● The next Earnings report is listed for November 12, 2026.

Scienture Holdings, Inc. (NASDAQ:SCNX), a small pharmaceutical company, has had a busy start to October. A 1-for-25 Reverse Stock Split took effect on October 5, and the company has announced formulary additions and distribution agreements for its products. With the next earnings report listed for November 12, several catalysts could shape how the market views the company in coming weeks. Because the company is small, with only a handful of employees reported in market data, outcomes may be sensitive to individual contracts and timing.

Latest Company Context

Scienture develops and commercialises treatments for central nervous system and cardiovascular conditions. Its 8-K stated that the reverse split became effective before the market opened on October 5, 2026, with trading on a split-adjusted basis under the same symbol, and that the aim is to help maintain compliance with Nasdaq's minimum bid price requirement. Shares outstanding were 41,064,146 at September 30, with about 1,642,565 expected afterwards. For the second quarter, revenue was $343,639, versus $56,325 in the first quarter, and the net loss narrowed to $2.82 million. Cash, cash equivalents and restricted cash were about $11.2 million at June 30. Recent headlines also cited Arbli formulary additions at three pediatric hospitals.

Key Business Drivers

Revenue is still small, so commercial execution is central. The company has begun launching REZENOPY, a naloxone nasal spray, and said it secured formulary coverage with a large national health plan. For Arbli, a losartan oral suspension, payer coverage expanded by about 12.5 million covered lives, according to the company. Headlines in September referred to distribution arrangements, including one involving addiction clinics. The company has also described a strategy of building growth through niche drug products, as presented at an investor conference in September. Management has said it expects revenue to accelerate in the second half of 2026 and into 2027 and sees a path toward profitability in 2027.

What Investors Should Watch

The next earnings report is listed for November 12, 2026, and may show whether launch activity is turning into higher sales. Investors might watch revenue growth from the second quarter base, Operating Expense trends, and cash use against the $11.2 million balance reported at June 30. The reverse split may affect per-share comparisons and trading liquidity, and companies often need to show sustained compliance with Nasdaq requirements afterwards. Further formulary or payer decisions, Patent news and any financing activity could also be catalysts. Dilution is a general consideration for small companies that raise capital. Progress on the pipeline products, including SCN-102 and SCN-104, may also be disclosed over time. Investors may also look for commentary on gross margin, which the company reported at about 97.7 percent in the second quarter on a very small revenue base.

A Reverse Split, New Launches and a Very Small Revenue Base

Scienture enters the final quarter of 2026 with launches under way, a restructured share count and an earnings date on the calendar. The company reports narrowing losses and rising sales from a very low base, while profitability remains a management goal rather than a result. A split alone does not change the underlying value of a company, and share prices after reverse splits can be volatile.